Friday 13-11-2009 (9:00–19:00)
9:00 Welcome Coffee, Registration
9:20 Ewa Jassem and Peter Valent Welcome and Opening
SESSION I: Update of Networking in Europe and in the US
9:30–11:00 Chair: Peter Valent, Dean D. Metcalfe
9:30 Peter Valent ECNM: Current Status and Plan for the Next Decade
9:45 Wolfgang R. Sperr The ECNM Registry
10:00 Karin Hartmann Mastocytosis ECNM ID Card for Patients in Europe
10:15 Boguslaw Nedoszytko, Jaroslaw Skokowski Cell Banking, DNA Banking, and Serum Banking in the ECNM
10:30 Marek Niedoszytko The Polish Network on Mastocytosis and Presentation of the Gdansk ECNM Center of Excellence
10:45 Coffee Break
11:15 Ulrich Blank & Stephan Bischoff & Gunnar Nilsson Mast Cells: Basic Science Networking in Europe and Applications to the EU
11:30 Peter Valent & Knut Brockow EU Calls and Possibilities for Application of ECNM partners
11:45 General Discussion
12:15 Lunch
SESSION II: New Diagnostic and Prognostic Parameters
13:15–15:00 Chair: Boguslaw Nedoszytko, Karl Sotlar
13.15. Dean D. Metcalfe Critical Signaling Nodes in Mast Cell Proliferation and Activation
13:30 Jasper van Doormaal Do biochemical markers predict Systemic Involvement in Mastocytosis?
13:45 Boguslaw Nedoszytko Genomic Background Factors Predicting Systemic Involvement in Mastocytosis
14:00 Hans-Peter Horny Extramedullary Involvement in Mastocytosis
14:15 Luis Escribano, Ivan Alarez-Twose New Prognostic Markers in SM: The REMA Data
14:30 Dean D. Metcalfe, Todd Wilson KIT Isoforms in Haematologic Disorders
14:45 Karoline V. Gleixner KIT-independent Pathways and Targets in SM
15:00 Coffee Break
SESSION III: Treatment of Mediator Symptoms in Mastocytosis
15:30–16.30 Chair: C. Akin, E. Jassem
15:30 Joanne Oude Elberink, Marek Niedoszytko Insect Venom Immunotherapy in Mastocytosis
15:45 Magdalena Lange, Joanna Renke Clinical Aspects of Pediatric Mastocytosis
16:00 Massimo Triggiani Mastocytosis and Pregnancy
16:15 Ewa Jassem Pretreatment before Surgery in Patients with Mastocytosis
16:30 Coffee Break
SESSION IV: Treatment of ASM and MCL
16.45–19:00 Chair: Andrzej Hellmann, Hanneke Kluin-Nelemans
16.45 Jason Gotlib Effects of Midostaurin in ASM, MCL, and SM-AHNMD
17:00 Emir Hadzijusufovic Effects of Histamine Receptor Antagonists on Mast Cells
17:15 Cem Akin New TKI and other Drugs: Update and Hope for the Future
17:30 Peter Valent & Dean D. Metcalfe Discussion on Drug Safety and Patient Selection for Clinical Trials
17.45. Judit Varkonyi Case Presentation: SM with Signs of Myeloproliferation, MGUS, and Recurrent Hydrothorax controlled by IFN
18:00 Coffee break
SESSION V: Short Communications of Unpublished Key Observations (5 minutes + 5 minutes discussion time)
18:15-19:00 Chair: Michał Woźniak, Hans-Peter Horny
18:15 Hans-Peter Horny MCL-CML or CML-MCL or a Typographical Error
18:25 Anders Jönsson Multiple Endocrine Neoplasia Type 1 in a Patient with Systemic Mastocytosis
18:35 Bartosz Wasag A novel Germline Mutation (p.N822I) in KIT Associated with Cutaneous Mastocytosis
18:45 Andrzej Mital, Andrzej Hellmann A case of aggressive systemic mastocytosis (ASM) with exon 9 KIT mutation and good response to imatinib
18:55 Hans-Peter Horny Histopathology of Mastocytosis involving the Gastrointestinal Tract: Diagnostic Criteria
Saturday 14-11-2009 (9:00-14:00)
SESSION VI: Skin involvement in Mastocytosis
9:00–10.30 Chair: Knut Brockow, Karin Hartmann
9:00 Andrzej Słomiński, Michał A. Żmijewski Neuroendocrinology of the Skin and Relationship to Mast Cells
9:15 Karin Hartmann Standards in Therapy of Cutaneous Mastocytosis
9:30 Knut Brockow Scoring of Skin-Related Symptoms and Evaluation of Treatment Responses
9:45 Markus Maurer Miltefosine in Cutaneus Mastocytosis
10:00 Coffee Break
SESSION VII: Molecular Biology and KIT mutations
10:30-11:30 Chair: Michel Arock, Marek Niedoszytko
10:30 Michał Woźniak Impact of redox signalling in mast cell contribution to inflammatory arthritis.
10:45 Karl Sotlar KIT Mutations and Other Molecular Defects in SM
11:00 Gunnar Nilsson Regulation of Survival and Apoptosis in normal and Neoplastic Human Mast Cells
11:15 Barbara Peter & Peter Valent Effects of Obatoclax on Neoplastic Mast Cells
11:30 Coffee Break
SESSION VIII: Novel Concepts about Mast Cells
12:00-13:30 Chair: Dean D. Metcalfe, Peter Valent
12:00 Tracy George Myelomastocytic Leukemia versus Mast Cell Leukemia versus SM-AML: A Diagnostic Challenge
12:15 Cem Akin Clinical and Laboratory Signs and Features of Mast Cell Activation
12:30 Andreas Reiter c-KIT Allele Burden in Patients with Systemic Mastocytosis
12:45 Marek Niedoszytko Gene Expression Analysis in Mastocytosis
13:00 Hans-Peter Horny Expression of CD30 in Neoplastic Mast Cells in Systemic Mastocytosis
13:15 Sabine Cerny-Reiterer, Peter Valent STAT5 Expression and Activation in Systemic Mastocytosis
13:30 Ewa Jassem and Peter Valent Closing Remarks
13:45 General Discussion
14:00 End of the Meeting